The Expanding Role of Dupilumab in Dermatology: Beyond Atopic Dermatitis

Dupilumab, a monoclonal antibody targeting interleukin-4 (IL-4) and interleukin-13 (IL-13), has revolutionized the management of atopic dermatitis (AD) since its approval in 2017. However, emerging evidence suggests its potential efficacy in treating a broader spectrum of dermatological conditions, prompting dermatologists to explore its expanding indications. Current Indications of Dupilumab Initially approved for moderate to severe atopic dermatitis, dupilumab has demonstrated significant improvements in clinical endpoints, such as the Eczema Area and Severity Index (EASI) and the Patient-Oriented Eczema Measure (POEM). Its favorable safety profile and ability to provide rapid relief from symptoms have made it a first-line therapy for AD. Expanding Indications Beyond AD, dupilumab is now being investigated for additional dermatological conditions: Chronic Rhinosinusitis with Nasal Polyps (CRSwNP): Clinical trials have shown promising results for dupilumab in treating CRSwNP, characterized by inflammation and polyp formation in the nasal passages. The therapy has demonstrated significant improvements in nasal congestion, loss of smell, and overall quality of life. Asthma: Although primarily a respiratory condition, asthma often coexists with dermatological issues. Dupilumab's dual action on IL-4 and IL-13 may address both conditions simultaneously, thus providing comprehensive management for patients suffering from atopic dermatitis and asthma. Chronic Urticaria: Recent studies have highlighted dupilumab's potential in chronic spontaneous urticaria, offering a new treatment avenue for patients unresponsive to traditional therapies. The mechanism of action may help reduce the inflammatory mediators responsible for urticaria. Psoriasis: While primarily targeted therapies exist for psoriasis, dupilumab has shown efficacy in some patients, particularly those who are also suffering from atopic dermatitis. Early trials suggest that it may improve psoriasis severity score